RxDoctor Payments Data

Mary Daly

Psychiatric/Mental Health · Saginaw, MINPI 1679668313

Payments from drug & device makers

$1,552in general payments, 2019–2025

Across 63 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$683
  • Johnson & Johnson$410
  • Otsuka America Pharmaceutical, Inc.$118
  • Lundbeck LLC$106
  • Atricure, Inc.$86
  • Alkermes, Inc.$76
  • plus $73 from 2 others

What the payments were for

  • Food & beverage$1,49396%
  • Education$594%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,552 in reported general payments places this provider in the 70th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$14,339
Medicare patients
29
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate29$88,828
TrintellixVortioxetine Hydrobromide29$14,860
Wellbutrin SrBupropion Hcl12$10,243
Paliperidone ErPaliperidone31$7,355
Lamotrigine ErLamotrigine23$4,602
Venlafaxine Hcl ErVenlafaxine Hcl59$2,287
Trazodone Hcl123$1,319
Methylphenidate Hcl27$1,300
Olanzapine57$1,293
Buspirone Hcl92$1,169
Escitalopram Oxalate91$1,058
Lamotrigine121$1,003
Clozapine12$983
Oxcarbazepine50$967
Duloxetine Hcl77$920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$410$88,82829 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$22$14,86029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →